Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2006 / Cilt: 32 - Sayı: 1

Comparison of EAU and AUA guidelines in diagnosis and treatment of BPH

BPH tanı ve tedavisinde EAU ve AUA kılavuzlarının karşılaştırılması

Pages
110–117
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Both guidelines present very rich information regarding the diagnosis and management of BPH under the lights of “evidence-based medicine” and they are of utmost importance for every urologist who treats LUTS of aging men.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The treatment of benign prostatic hyperplasia (BPH), which is the most common cause of lower urinary tract symptoms (LUTS) of aging male, has been rapidly developing.
📊
Key Findings & Data:Overflowing the borders of “evidence-based medicine”, intense advertisement efforts of some treatment modalities for BPH in mass media of our country let to a big confusion not only in the minds of the patients but also in men without LUTS.
💡
Conclusion & Impact:Both guidelines present very rich information regarding the diagnosis and management of BPH under the lights of “evidence-based medicine” and they are of utmost importance for every urologist who treats LUTS of aging men.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Tanı · Prostat hiperplazisi · Kılavuz

Abstract

Introduction: The treatment of benign prostatic hyperplasia (BPH), which is the most common cause of lower urinary tract symptoms (LUTS) of aging male, has been rapidly developing. New treatment options, especially, in the field of medical and minimal invasive treatment have been introduced in recent years. Overflowing the borders of “evidence-based medicine”, intense advertisement efforts of some treatment modalities for BPH in mass media of our country let to a big confusion not only in the minds of the patients but also in men without LUTS. Therefore, the responsibility of the urologist in clarifying this confusion and donating the patients with true information has been increased. In this review, we analyzed in a comparative manner, the BPH guidelines of American Urology Association (AUA) and European Urology Association (EAU). Although, there are certain differences between two guidelines, basic ideology of approaching to BPH is similar. Both guidelines present very rich information regarding the diagnosis and management of BPH under the lights of “evidence-based medicine” and they are of utmost importance for every urologist who treats LUTS of aging men.

Özet

Yaşlanan erkeklerde alt üriner sistem semptomlarının (AÜSS) en sık nedeni olan benin prostat hiperplazisinin (BPH) tedavisindeki gelişmeler büyük bir hızla devam etmektedir. Son yıllarda, özellikle medikal tedavi ve minimal invaziv cerrahi alanlarında yeni birçok seçenek ortaya çıkmıştır. Henüz “kanıta dayalı tıp” çerçevesinde başarısı ispatlanmamış, yada ancak belirli hasta gruplarında önerilebilecek bir çok seçeneğin reklamı ülkemizde yazılı ve görsel basında geniş yer alarak hastalarda, hatta yakınması olmayan erkeklerde dahi kafa karışıklığına yol açmaya başlamıştır. Bu nedenle, biz üroloji uzmanı hekimlere yaratılan yanlış bilgilendirmeye karşı hastalarımızı aydınlatmak konusunda düşen sorumluluk gün geçtikçe artmaktadır. Bu yazıda, dünyada iki en yetkin üroloji derneği olan Amerikan Üroloji Birliği (AUA) ve Avrupa Üroloji Birliği (EAU) tarafından kanıta dayalı tıp ışığında hazırlanan BPH’ye yaklaşım kılavuzları karşılaştırmalı olarak değerlendirilmiştir. Kılavuzlar arasında bazı farklar olmakla birlikte temel yaklaşımlar birbirine benzerdir. Yaşlanan erkeklerde AÜSS tedavisinde kafa karışıklığının giderilmesinde her iki kılavuz içindeki bilgilerin özümsenmesi büyük önem taşımaktadır.

🔖

Cite This Article

TARCAN, T., YAZICI, C. (2006). Comparison of EAU and AUA guidelines in diagnosis and treatment of BPH. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 32 - Sayı: 1, 110–117. https://ajindex.com/articles/328365

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. De la Rosette J, Madersbacher S, Alivizatos G: EAU guidelines on benign prostatic hyperplasia. Eur Urol 46: 547-554, 2004
  2. Roehrborn CG, McConnell JD, Barry MJ, et al: AUA guidelines on the management of benign prostatic hyperplasia (BPH). J Urol 170: 530-547, 2003
  3. Foreman WH, Messing EM: Bladder cancer: Natural history, tumor markers, and early detection strategies. Semin Surg Oncol. 13: 299-306, 1997
  4. Messing EM, Young TB, Hunt VB, et al: The significance of asymptomatic microhematuria in men 50 or more years old: Findings of a home screening study using urinary dipsticks. J Urol, 137: 919-922, 1987
  5. Mohr DN, Offord KP, Melton LJ: Isolated asymptomatic microhemeturia: A cross-sectional analysis of testpositive and test-negative patients. J Gen Intern Med, 2: 318-324, 1987
  6. Polascik TJ, Oesterling JE, Partin AW: Prostate specific antigen: A decade of discovery-what we have learned and where we are going. J Urol, 162: 293-306, 1999
  7. Roehrborn CG, McConnell JD, Saltzman B, et al: PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Uro 42; 1-6, 2002
  8. Roehrborn CG, Malice MP, Cook TJ, et al: Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology, 58: 210-216, 2001
  9. Meigs JB, Mohr B, Barry MJ, et al: Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiology 54, 935-944, 2001
  10. Mebust WK, Holtgrewe HL, Cockett AT: Transurethral prostatectomy: immediate and postoperative complications. A comparative study of 13 participating instituteons evaluating 3885 patients. J Urol, 141: 243-247, 1989
  11. Gerber GS, Goldfisher ER, Karrison TG, et al: Serum creatinine measurement in men with lower urinary tract symptoms secondary to benign prostatic hperplasia. Urology 49: 697-702, 1997
  12. McConnel JD, the MTOPS Steering Committee: The long term effects of medical therapy on the progression of BPH: Results from the MTOPS trial. J Urol, 167: 1042-1044, 2002
  13. Barry MJ, Fowler FJ, O’Leary MP: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol, 148: 1549-57,1992
  14. Wasson JH, Reda DJ,